People · Operator
Named in public records as an officer, director or promoter · active 2012–2018 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Athenex, Inc. | — | Pharmaceuticals | Series C | $366.7M | $2.1B | 2012 |
| Atea Pharmaceuticals, Inc. | — | Biotechnology | Series D+ | $175.9M | $4.4B | 2018 |
| Alzheon, Inc. | — | Biotechnology | Series D+ | $172.5M | $1.6B | 2014 |
Jean-Pierre Sommadossi at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jean-Pierre Sommadossi on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Franklin Berger | 2 | 7 |
| Michael Murphy | 1 | 21 |
| BIHUA CHEN | 1 | 14 |
| Gerald Chan | 1 | 13 |
| Dennis Langer | 1 | 9 |
| Scott Minick | 1 | 7 |
| Franz Hefti | 1 | 6 |
| Robert Silverman | 1 | 5 |
| Christopher Noel Dunn | 1 | 5 |
| Michael Aceti | 1 | 4 |
| Fan Yu | 1 | 4 |
| David Nikodem | 1 | 4 |
| Simon Pedder | 1 | 3 |
| Jeffrey Yordon | 1 | 3 |
| Grigory Borisenko | 1 | 3 |
| Johnson Lau | 1 | 3 |
| Frank Yu | 1 | 3 |
| Charles Lannon | 1 | 3 |
| Martin Tolar | 1 | 2 |
| Jean-Pierre Garnier | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.